Improving predictions about brain cancer outcomes with the right imaging criteria

A paper published in the Journal of Clinical Oncology, titled “Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204,” examines how different imaging criteria can be used to assess brain tumor responses in patients with melanoma treated with immunotherapy drugs.

The researchers identified one imaging method that was more accurate in predicting survival compared to others. While further work is needed, they say the study is promising and highlights the importance of more consistent imaging standards in clinical trials.

For the study, the researchers looked at different measurements of brain metastases on MRI scans taken over the course of two years or longer for patients in a multi-center Phase II clinical trial evaluating an immunotherapy for brain cancer.

They took into consideration the patient’s response to the therapy, including progression-free survival (PFS) and overall survival (OS), to determine which set of criteria was most predictive of patient outcome.

They found that a modified imaging approach (mRECIST) and volumetric measurements (3D size analysis) were more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies when evaluating treatment response.

Overall, these findings aim to improve how oncologists evaluate and treat brain metastases in cancer patients.

The researchers are developing automatic segmentation technology to improve the consistency of 3D tumor measurements, with the goal of making a standard tool for evaluating brain metastases.

A paper published in the Journal of Clinical Oncology, titled “Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204,” examines how different imaging criteria can be used to assess brain tumor responses in patients with melanoma treated with immunotherapy drugs.

The researchers identified one imaging method that was more accurate in predicting survival compared to others. While further work is needed, they say the study is promising and highlights the importance of more consistent imaging standards in clinical trials.

For the study, the researchers looked at different measurements of brain metastases on MRI scans taken over the course of two years or longer for patients in a multi-center Phase II clinical trial evaluating an immunotherapy for brain cancer.

They took into consideration the patient’s response to the therapy, including progression-free survival (PFS) and overall survival (OS), to determine which set of criteria was most predictive of patient outcome.

They found that a modified imaging approach (mRECIST) and volumetric measurements (3D size analysis) were more accurate in predicting survival compared to other methods. These approaches worked well even for small tumors, suggesting they should be included in future studies when evaluating treatment response.

Overall, these findings aim to improve how oncologists evaluate and treat brain metastases in cancer patients.

The researchers are developing automatic segmentation technology to improve the consistency of 3D tumor measurements, with the goal of making a standard tool for evaluating brain metastases.